

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.		FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/493,427 01/29/2000		01/29/2000	Patrick L. Iverson	0450-0025.30	2225
22918	7590	01/29/2002			
PERKINS (	COIE L	LP	EXAMINER		
P.O. BOX 2 MENLO PA		94026		EPPS, JANET L	
				ART UNIT	PAPER NUMBER
			٠	1635 DATE MAILED: 01/29/2002	12

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Advisory Action	09/493,427	IVERSON ET AL.				
7.4477.56. <b>3</b>	Examiner	Art Unit				
	Janet L Epps	1635				
The MAILING DATE of this communication appe	ars on the cover sheet with the c	correspond nce address				
THE REPLY FILED 16 January 2002 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.						
PERIOD FOR REPLY [check either a) or b)]						
a) The period for reply expiresmonths from the mailing date of the final rejection.  b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.  ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).  Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
1. A Notice of Appeal was filed on 16 January 2002. Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.						
2. The proposed amendment(s) will not be entered because:						
(a)  they raise new issues that would require furthous		see NOTE below);				
(b) ☐ they raise the issue of new matter (see Note below);						
(c) Methey are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or						
(d) they present additional claims without cancel	ing a corresponding number of t	finally rejected claims.				
NOTE: <u>See Continuation Sheet</u> .						
3. Applicant's reply has overcome the following reject	tion(s):					
4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).						
5. The a) affidavit, b) exhibit, or c) request for reconsideration has been considered but does NOT place the application in condition for allowance because:						
6. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.						
7. For purposes of Appeal, the proposed amendment(s) a) will not be entered or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.						
The status of the claim(s) is (or will be) as follows:						
Claim(s) allowed:						
Claim(s) objected to:						
Claim(s) rejected:						
Claim(s) withdrawn from consideration:						
8. The proposed drawing correction filed on is a) approved or b) disapproved by the Examiner.						
9. Note the attached Information Disclosure Statement(s)( PTO-1449) Paper No(s)						
10. Other:						
S. Patent and Trademark Office	-	<del></del>				

## Continuation Sheet (PTO-303) 09/493,427

Continuation of 2. NOTE: Applicants have amended claim 23 to recite wherein the morpholino antisense is administered "to the patient, by placing the compound in contact with, or injecting the compound into, the treated region of the vessel." However, it remains that the claimed method does not state that the sample of body fluid is isolated particularly from vessel cells, therefore it is unclear how this method of detection would produce results particularly regarding the interaction of a morpholino antisense compound with c-myc mRNA specifically in vessel cells. Additionally, it is noted that the method recites that the antisense compound is administered in a region of the vessel, and not specifically in the vessel cells.

Furthermore, Applicants have added new claims 26-27 which recite 5 different modes of administering the antisense compound to a patient. These new limitations would require further search and consideration.

JOHN L. LEGUYADER
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600